My Top 2 AI Stocks Flying Under the Radar for May 2026

Aehr Test Systems is highlighted as a high-momentum AI stock, up 379% YTD and 961% over the past year, supported by a growing contract pipeline that reached about $92 million after a $41 million hyperscaler deal. ServiceNow looks more attractive after a 42% YTD decline, with 22% to 22.5% subscription revenue guidance for 2026, $27.7 billion in RPO, and a lowered valuation at 21x forward earnings. The article is mostly a bullish valuation-and-growth screen rather than a new company-specific catalyst.

Analysis

AEHR’s setup is less about near-term earnings power than about whether its backlog converts into repeatable fab/tooling demand. The market is likely pricing in a step-function adoption cycle in wafer-level test, but that typically comes with lumpy recognition, customer concentration, and a high probability of “air pocket” quarters if a single hyperscaler defers capex. The second-order winner here is not just AEHR; it is any downstream equipment vendor that can attach to AI silicon qualification as production scales, while traditional discrete-test vendors risk being displaced if wafer-level yields improve faster than expected.

NOW’s drawdown looks more like a timing/positioning reset than a structural break, which matters because enterprise software multiples usually re-rate on forward visibility, not just current bookings. The key is that delayed contract closes do not destroy demand; they shift it, and that creates a cleaner entry window if the stock is no longer paying for perfection. The real incremental question is whether AI features compress workflow software spend over the medium term or actually expand the TAM by increasing system-of-record complexity; in the near term, the latter is more likely, especially with cybersecurity attach potentially deepening wallet share.

The consensus seems to be treating AEHR as a pure momentum AI name and NOW as a damaged secular compounder. That misses the asymmetry: AEHR likely has the larger operating leverage but also the higher probability of a sharp reversal if bookings normalize, while NOW has the better risk-adjusted setup because guidance revisions and RPO growth can re-anchor valuation over the next 1-2 quarters. The broader tell is that investors are still over-rewarding anything with AI in the label, but under-appreciating boring, recurring software platforms that can monetize AI without being disrupted by it.

Key Decisions for Investors

• Long NOW on further weakness or after the next close-confirmation, targeting a 3-6 month re-rating as deferred contracts convert; use a 10-15% trailing stop because the main risk is another guidance reset, not valuation alone.
• Avoid chasing AEHR after the move; if initiating, structure as a small starter long only on a 20-25% pullback, since the risk/reward is skewed by backlog concentration and lumpy revenue conversion.
• Pair trade: long NOW / short a basket of high-multiple AI hardware beneficiaries with weaker visibility, to express the view that recurring software will outlive near-term hardware exuberance on a risk-adjusted basis.
• For more aggressive exposure, buy AEHR calls with 2-4 month maturity only if you expect another large hyperscaler order; the trade is a convex continuation bet, but premium decay is high if bookings slow.
• Monitor NOW’s next two quarters for RPO and subscription guidance follow-through; if those stay intact, add on confirmation because the stock can re-rate quickly once the market stops discounting the contract delays.